Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$183.90M$183.90M+5.4% vs Q2 2025 Net Income$30.35M$30.35M−2.2% vs Q2 2025 EPS Diluted$0.67$0.67+4.7% vs Q2 2025 Gross Profit$93,470,000+8.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$51,324,000+44.2% Free Cash Flowderived$42,733,000+70.7% Margins · derivedGross margin50.8%+1.2 pt vs Q2 2025
Operating margin21.6%−2.6 pt vs Q2 2025
Net margin16.5%−1.3 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end